Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lucia Poncette"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5b055797f7f14ca79dd2c85ac3b4ab7b
Autor:
Elisa Kieback, Mikhail Steklov, Lucia Poncette, Lia Walcher, Lorenz Knackstedt, Friederike Knipping, Paul Najm, Paul Zschimmer, Panagiota A Sotiropoulou, Marleen van Loenen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ea92aa3a67334504abf4152d1fbfd389
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Adoptive transfer of patient’s T cells, engineered to express a T cell receptor (TCR) with defined novel antigen specificity, is a convenient form of cancer therapy. In most cases, major histocompatibility complex (MHC) I-restricted TCRs
Externí odkaz:
https://doaj.org/article/9ee2fb67fa174601b37ca3681f3fb742
BackgroundAdoptive transfer of patient’s T cells, engineered to express a T cell receptor (TCR) with defined novel antigen specificity, is a convenient form of cancer therapy. In most cases, major histocompatibility complex (MHC) I-restricted TCRs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66a0b3cc4af7def608a5dac78c2ad13
http://edoc.mdc-berlin.de/23123/2/23123suppl.pdf
http://edoc.mdc-berlin.de/23123/2/23123suppl.pdf
Publikováno v:
Current opinion in immunology. 74
The focus in cancer immunotherapy has mainly been on CD8 T cells, as they can directly recognize cancer cells. CD4 T cells have largely been neglected, because most cancers lack MHC II expression and cannot directly be recognized by CD4 T cells. Yet,
Autor:
Alexei Leliavski, Lorenz Knackstedt, Jennifer Oduro, Claudia Selck, Arunraj Dhamodaran, Thomas Blankenstein, Elisa Kieback, Lucia Poncette
Publikováno v:
Cancer Research. 82:5507-5507
Background T cell receptor (TCR)-engineered T cell therapy (TCR-T) is a promising therapeutic modality to address key limitations of targeting solid tumors. Neoantigens are excellent therapeutic targets for TCR-T cell therapy, because they are highly
Publikováno v:
Journal of Clinical Investigation. 129:324-335
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the im
Publikováno v:
The Journal of Experimental Medicine
Chen et al. demonstrate that human MHC selects a larger human TCR repertoire than mouse MHC. They show how humans optimized TCR diversity and suggest that CDR3 length adjusts for different V segment–MHC affinity.
For thymic selection and respo
For thymic selection and respo
Autor:
Alexander, Visekruna, Josephine, Ritter, Tatjana, Scholz, Lucia, Campos, Anna, Guralnik, Lucia, Poncette, Hartmann, Raifer, Stefanie, Hagner, Holger, Garn, Valerie, Staudt, Tobias, Bopp, Sebastian, Reuter, Christian, Taube, Karin, Loser, Magdalena, Huber
Publikováno v:
European journal of immunology. 43(3)
Similar to T-helper (Th) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (Tc9) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence
Autor:
'Lucia Poncette
Publikováno v:
Julia Bluhm